By: Ryan Sieg, Brett Jones, Wei Wang, Ameer B. Khoso, Allan H. Young, Muhammad Ishrat Husain
Growing evidence suggests a link between inflammation and bipolar disorder (BD). Trials of repurposed immunomodulatory drugs in patients with BD have reported mixed results. Utilizing biomarkers to stratify treatment has been suggested as a way to personalize treatment with immunomodulatory drugs in neuropsychiatric disorders and improve outcomes. The neutrophil to lymphocyte ratio (NLR) is one such candidate biomarker but is yet to be extensively assessed in bipolar depression and in populations in low and middle-income settings.